{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:25:09Z","timestamp":1790357109194,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA08748"],"award-info":[{"award-number":["P30 CA08748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjuvant anti-PD1 treatment improves relapse-free survival (RFS) but has not been shown to improve overall survival (OS) in melanoma and is associated with risks of immune-related adverse events (irAEs), some permanent. We identified factors patients consider in deciding whether to undergo adjuvant anti-PD1 treatment and assessed prospective health-related quality of life (HRQoL), treatment satisfaction, and decisional regret.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients with stage IIIB-IV cutaneous melanoma and free of disease, were candidates for adjuvant anti-PD1 immunotherapy, and had not yet discussed adjuvant treatment options with their oncologist were eligible. Participants viewed a 4-minute informational video tailored to their disease stage which communicated comprehensive, quantitative information about the risk of relapse both with and without adjuvant treatment, and risks of each irAE before deciding whether or not to opt for adjuvant therapy. We collected data on demographics, HRQoL, and attitudes toward adjuvant treatment over 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>14\/34 patients (41%) opted for adjuvant anti-PD1 immunotherapy, 20\/34 (59%) opted for observation. Patients choosing adjuvant immunotherapy scored higher on HRQoL social well-being at pre-treatment, were more likely to endorse positive statements about adjuvant immunotherapy, and to perceive that their physician preferred adjuvant therapy. They had lower decisional regret and higher satisfaction, even if they experienced toxicity or recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When provided with comprehensive quantitative information about risks and benefits of adjuvant anti-PD1 immunotherapy, 20\/34 (59%) of patients opted for observation. Patients choosing adjuvant immunotherapy had lower decisional regret and higher satisfaction over time even if they had poorer outcomes in treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac266","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T17:44:32Z","timestamp":1671644672000},"page":"351-357","source":"Crossref","is-referenced-by-count":15,"title":["Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy"],"prefix":"10.1093","volume":"28","author":[{"given":"Thomas M","family":"Atkinson","sequence":"first","affiliation":[{"name":"Department of Psychiatry & Behavior Sciences, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Hay","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Behavior Sciences, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Young Kim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Behavior Sciences, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Schofield","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Behavior Sciences, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Postow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Momtaz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Betof","family":"Warner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K","family":"Callahan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D","family":"Wolchok","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"},{"name":"Ludwig Institute for Cancer Research , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Behavior Sciences, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-0811","authenticated-orcid":false,"given":"Paul B","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med."},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol."},{"issue":"8","key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"e003188","DOI":"10.1136\/jitc-2021-003188","article-title":"Adjuvant nivolumab for stage III\/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival","volume":"9","author":"Mandala","year":"2021","journal-title":"J ImmunoTher Cancer."},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med."},{"issue":"20","key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med."},{"key":"2023040615572881900_","first-page":"183","article-title":"Surgical resection as the treatment of choice for melanoma metastatic to the lung","volume":"8","author":"Ollila","year":"1998","journal-title":"Chest Surg Clin N Am"},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/(SICI)1096-9098(199908)71:4<209::AID-JSO1>3.0.CO;2-2","article-title":"Metastasectomy for recurrent stage IV melanoma","volume":"71","author":"Ollila","year":"1999","journal-title":"J Surg Oncol"},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/cncr.23424","article-title":"Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire","volume":"112","author":"Cormier","year":"2008","journal-title":"Cancer"},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1200\/JCO.2005.07.171","article-title":"Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients","volume":"23","author":"Jansen","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11136-013-0520-8","article-title":"Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (FACIT TS) measures","volume":"23","author":"Peipert","year":"2014","journal-title":"Qual Life Res"},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0272989X03256005","article-title":"Validation of a decision regret scale","volume":"23","author":"Brehaut","year":"2003","journal-title":"Med Decis Making"},{"key":"2023040615572881900_","volume-title":"R: A Language and Environment for Statistical Computing","author":"Team RC.","year":"2022"},{"key":"2023040615572881900_","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/351\/49789457\/oyac266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/351\/49789457\/oyac266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T06:22:45Z","timestamp":1701584565000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/4\/351\/7028558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2,6]]},"published-print":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac266","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,2,6]]}}}